ArticleInfection and drug resistance2023
Emergence of OXA-484-Producing
Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Limits of rapid diagnostics: genomic and structural insights into OXA-48-like mediated carbapenem resistance inFrontiers in microbiology · 2026Article
- Genomic characterizations ofEmerging microbes & infections · 2025Article
- MicroRNA warfare: how chickens combatFrontiers in cellular and infection microbiology · 2025Article
- Oxacillinase-484-Producing Enterobacterales, France, 2018-2023.Emerging infectious diseases · 2024Article
- Emergence of plasmid-borneMicrobiology spectrum · 2024Article
- Hypermucoviscous Multidrug-ResistantPathogens (Basel, Switzerland) · 2024Article
- Molecular, Genetic, and Biochemical Characterization of OXA-484 Carbapenemase, a Difficult-to-Detect R214G Variant of OXA-181.Microorganisms · 2024Article
- In Vitro Activity of "Old" and "New" Antimicrobials against theAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The frequent and inappropriate use of antibiotics has caused a dramatic rise in the number, species, and degree of multi-drug resistant bacteria, making them more prevalent and difficult to treat. In this context, the aim of the present study was to characterize the OXA-484-producing strains isolated from a perianal swab of a patient by using whole-genome analysis. Patients and Methods: In this study, carbapenemase-producing Results: The antimicrobial susceptibility pattern of Conclusion: Herein, we described the first genome sequence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.